bleeding disorders
Skip this Video
Download Presentation
Bleeding Disorders

Loading in 2 Seconds...

play fullscreen
1 / 46

Bleeding Disorders - PowerPoint PPT Presentation

  • Uploaded on

Bleeding Disorders. Meera Shreedhara 8/25/08 . What is it?. A bleeding disorder is an acquired or inherited tendency to bleed excessively. Mechanisms of bleeding. Vascular Integrity Platelets Clotting factors Fibrinolysis Derangement of any of these factors can cause abnormal bleeding.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' Bleeding Disorders' - gervaise-odin

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
bleeding disorders

Bleeding Disorders

Meera Shreedhara


what is it
What is it?
  • A bleeding disorder is an acquired or inherited tendency to bleed excessively
mechanisms of bleeding
Mechanisms of bleeding
  • Vascular Integrity
  • Platelets
  • Clotting factors
  • Fibrinolysis
  • Derangement of any of these factors can cause abnormal bleeding
key to diagnosis
Key to diagnosis
  • History
  • History
  • History
bleeding history
Bleeding history
  • Epistaxis
  • Gingival hemorrhage
  • Mucosal Bleeding
  • Heavy Menses
  • Child birth
  • Easy bruisability
  • Bleeding following tooth extractions
  • Hematomas
  • Bleeding following surgery
  • Hemarthrosis
medication history
Medication History
  • Aspirin
  • Warfarin
  • B- Lactam antibiotics
  • Clopidogrel and other antiplatelet agents
  • Herbal medications.
nutritional history
Nutritional history
  • Vit K deficiency
  • Vit C deficiency
  • Broad spectrum antibiotics
  • Should the pt undergo a limited or extensive workup?
  • Is this acquired or hereditary?
  • Is this likely a disorder of clotting factors,platelets, fibrinolysis or vWF?
  • Do medications or intercurrent illnesses play a role?
  • What is the immediate cause for which a workup is being done?
  • Deficiency of coagulation factors
    • Hemophilia
    • Fibrinogen deficiency
    • Von Willebrand disease
  • Platelet disorders
    • Glanzmann thrombasthenia
    • Bernard-Soulier syndrome
    • Platelet granule disorders
  • Fibrinolytic disorders
    • Alpha 2 antiplasmin deficiency
    • PAI 1 deficiency
  • Structural disorders
    • Hemorrhagic Telangiectasias
    • Ehler Danlos syndrome
  • Thrombocytopenis
  • Liver disease
  • Renal failure
  • Vit K deficiency
  • Acquired antibodies to coagulation factors
  • DIC
  • Drugs
  • Vascular
lab testing
Lab testing
  • Platelet count
  • Bleeding time-Measure of the interaction of platelets with the blood vessel wall.
    • Thrombocytopenia (platelet count usually below 50,000/microL),
    • Qualitative platelet abnormalities (eg, uremia),
    • von Willebrand disease (VWD),
    • Vascular purpura,
    • Severe fibrinogen deficiency
platelet function assay
Platelet function assay
  • Expose platelets within citrated whole blood to high shear (5,000 to 6,000/sec) within a capillary tube and monitor the drop in flow rate as the platelets form a hemostatic plug within the center of a membrane coated with collagen and either ADP or epinephrine
  • Abnormal closure times are an indication of platelet dysfunction, they are not specific for any disorder
  • The test is coagulation factor independent
  • PFA-100™ is more sensitive (>70 percent) than the bleeding time (20 to 30 percent) in detecting all subtypes of von Willebrand's disease (vWD)
  • Exception is type 2N vWD, in which the hemostatic defect resides in the Factor VIII binding site on vWF
platelet function assay1
Platelet function assay
  • Collagen/epinephrine closure time (CEPI-CT)- Abnormal in Aspirin intake
  • Collagen/adenosine diphosphate (CADT-CT)-Normal in aspirin intake
prothrombin time
Prothrombin time
  • Measure of the extrinsic pathway and common pathway
  • Bypasses the intrinsic pathway and uses thromboplastins to substitute for platelets
  • Within the combined pathway, factors VII, X, and prothrombin are vitamin-K dependent and are altered by warfarin
prolonged pt
Prolonged PT
  • Vitamin K deficiency
  • Liver disease, which decreases the synthesis of both vitamin K-dependent and -independent clotting factors.
  • Deficiency or inhibition of factors VII, X, II (prothrombin), V, or fibrinogen
  • The infrequent antiphospholipid antibodies (lupus anticoagulant phenomenon) with antiprothrombin activity
  • Heparin does NOT prolong the PT
  • Measures the intrinsic and common pathways of coagulation
  • Uses partial thromboplastins; they are incapable of activating the extrinsic pathway
  • Prolonged in deficiency of, or an inhibitor to, any of the clotting factors except for factor VII
  • Prolonged in the presence of Lupus Anticoagulant.
  • Used to monitor heparin activity
thrombin time
Thrombin time
  • Measure conversion of fibrinogen to fibrin monomers and the formation of initial clot by thrombin
  • Hypofibrinogenemia,
  • Dysfibrinogens
  • Increased fibrin split products
  • Heparin increases TT but not RT
factor deficiencies inhibitors
Factor deficiencies/ inhibitors
  • A prolonged aPTT can be due to a deficiency (or absence) of a coagulation factor or the presence of a coagulation factor inhibitor
  • Mixing studies help differentiate this
  • Lupus anticoagulants can result in a prolonged aPTT that is not correctable by the addition of normal plasma
  • Overcome by adding excess platelet phospholipid (particularly a hexagonal phase phospholipid) or by assessing the diluted Russell's viper venom time
  • Fibrin and fibrinogen degradation products (FDP) are protein fragments resulting from the action of plasmin on fibrin or fibrinogen
  • FDP assays do not differentiate between fibrin degradation products and fibrinogen degradation products
  • Fibrin D-dimers are degradation products of cross-linked fibrin
  • D-dimers specifically reflect fibrinolysis of cross-linked fibrin (ie, the fibrin clot) – so are more reliable indicators of thrombosis
  • Assays for plasminogen,
  • Tissue plasminogen activator (t-PA),
  • Alpha-2 antiplasmin,
  • Plasminogen activator inhibitor-1 (PAI-1),
  • Thrombin-activatable fibrinolysis inhibitor (TAFI).
normal pt and ptt
Normal PT and PTT
  • Thrombocytopenia
  • vWD
  • Factor 13 deficiency
  • Platelet dysfunction
  • Vascular purpuras
  • Psychogenic purpura
normal pt and prolonged aptt
Normal PT and Prolonged aPTT
  • Hemophilia A
  • Hemophilia B
  • Factor XI deficiency
  • Factor VIII inhibitor
    • Malignancy,
    • Clonal lymphoproliferative disorders,
    • Pregnancy,
    • Rheumatologic disorders
prolonged pt and normal aptt
Prolonged PT and normal aPTT
  • Factor VII deficiency
  • Warfarin therapy
  • Early liver disease
  • Early DIC
prolonged pt and ptt
Prolonged PT and PTT
  • Vit K deficiency
  • Liver disease
  • Warfarin treatment
  • Acquired inhibitor to factor V
  • Factor X deficiency- seen in Amyloidosis
  • DIC
acute promyelocytic leukemia
Acute Promyelocytic Leukemia
  • DIC is often seen at presentation or during treatment
  • Medical Emergency as Cerebral hemorrhage can occur in upto 4% of untreated pts
  • Promyelocytes seen on smear
  • Reciprocal translocation between the long arms of chromosomes 15 and 17, with the creation of a fusion gene, PML/RAR-alpha
  • Immediate initiation of ATRA induces de deifferentiation
  • Hemophilia A and B are X-linked recessive diseases
  • Severe disease <1 % factor activity,
  • Moderate disease- 1 to 5 %
  • Mild disease >5 %
  • The most common sites are into joints and muscles and from the gastrointestinal tract
  • The two components to therapy are treatment of active bleeding and inhibitor ablation via immune tolerance induction
  • Cryoprecipitate has high levels of factor VIII
  • Porcine Factor VIII
  • Recombinant human Factor VIII
  • The choice of factor VIII product usually is based upon safety, purity, and cost.
  • One international unit (IU) of clotting factor is that amount present in 1 mL of pooled normal plasma
  • Dose of F VIII (IU) = Weight (kg) x (Desired % increase) x 0.5
  • Depends on the clinical indication and the presence of inhibitors
von willebrand s disease
von Willebrand’s disease
  • Most common of the inherited bleeding disorders
  • In 1926, Erik von Willebrand described the first patient with the disease
  • Von Willebrand factor (VWF) binds to both platelets and endothelial components, forming an adhesive bridge between platelets and vascular subendothelial structures and between adjacent platelets at sites of endothelial injury
acquired von willebrand s disease
Malignant diseases

Monoclonal gammopathy of unknown significance

Multiple Myeloma

Non-Hodgkin's lymphoma

Chronic lymphocytic leukemia

Waldenstrom's macroglobulinemia

Essential thrombocythemiaPolycythemia vera

Chronic myelogenous leukemia

Wilms tumor

Other carcinomas

Immunologic disorders

Systemic lupus erythematosus

Other autoimmune diseases

Other disorders


Ventricular septal defect

Aortic stenosis

Mitral valve prolapse

Gastrointestinal angiodyplasia



Drugs and other agents

Valproic acid


Acquired von Willebrand’s disease
  • Replacement of vWF
  • EACA
  • Tranexamic acid
  • Recombinant factor 7
therapies other than factor replacement
Therapies other than factor replacement
  • EACA
  • Tranexamic Acid
  • Factor 7 inhibitor- Novoseven
liver disease vs dic
Liver disease Vs DIC
  • Low factor V levels can be used as evidence for either reduced hepatic synthetic function or increased consumption, as in DIC
  • Factor VIII is not manufactured by hepatocytes; factor VIII levels are usually normal or increased in liver disease